Kurs & Likviditet
|Lista||First North Denmark|
|2021-04-28||Ordinarie utdelning VIRO 0.00 DKK|
|2020-06-19||Ordinarie utdelning VIRO 0.00 DKK|
|2019-04-26||Ordinarie utdelning VIRO 0.00 DKK|
25.9.2020 15:06:06 CEST | ViroGates | Company Announcement
No 22-2020 - 25. September 2020
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that it has received an order from a new clinical routine customer in Spain, the University Hospital of Salamanca. The hospital is affiliated with the oldest university in Spain and is generally highly regarded for its clinical research. The hospital is a leading hospital in the region Castilla y León, and has an uptake population of around 300,000 inhabitants and 900 beds.
The implementation has followed a process of pilot use of the suPARnostic® TurbiLatex product and the hospital has decided to implement suPARnostic® TurbiLatex to improve triaging based on the underlying data from both international use but also experience elsewhere in the Spanish market. The hospital has on this background via the central purchasing department sent the first order to ViroGates for future clinical use in the emergency department.
Jakob Knudsen, Chief Executive Officer of ViroGates, says: ”We are really excited to supply our products for this leading regional hospital in Spain. The University Hospital in Salamanca has been using our product now in a pilot phase to get acquainted with the use, and has now expeditely decided to implement our product in clinical routine. The Hospital has made the first order today in connection with the official decision to implement suPARnostic® TurbiLatex in clinical routine.
The implementation is based on general triage of patients in the emergency department, but we have learned that the decision to implement our product is also driven by the large amounts of patients with positive Covid-19 tests seeking treatment at the Hospital currently.”
The announcement can be found at https://www.virogates.com/investor/announcements
For further information please contact:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: firstname.lastname@example.org
Västra Hamnen Corporate Finance
Tel. (+46) 40 200 250, email: email@example.com
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
- Jakob Knudsen, CEO, +45 2226 1355, firstname.lastname@example.org